Eli Lilly and Company (LLY) launched their blockbuster weight-loss drug in India. India one of the countries having the largest population may be a good market.
Their mainstream competitor Novo Nordisk’s Wegovy already been approved in India ready for market launch. Both pharma biggies are evaluating India as a major market within 10 years.
Mounjaro®
Mounjaro, the first and only GIP and GLP-1 receptor agonist approved for Type 2 diabetes. It is a single molecule that binds to glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide (GIP).
Tirzepatide
Tirzepatide is a drug that has attracted a lot of interest since it effectively treats type 2 diabetes and aids in weight loss. Tirzepatide is an agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP).
By targeting both receptors, tirzepatide can have a more dramatic effect on blood sugar control and weight reduction compared to GLP-1 receptor agonists alone.
Medical Information: Eli Lilly and Company
Last Modified:
